Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at Scotiabank

Aura Biosciences (NASDAQ:AURA) had its price objective upped by Scotiabank from $20.00 to $23.00 in a research report sent to investors on Friday morning, MarketBeat reports. The brokerage currently has a sector outperform rating on the stock.

A number of other research analysts have also weighed in on the stock. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. HC Wainwright increased their price objective on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday. JMP Securities increased their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, BTIG Research increased their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Trading Up 14.1 %

Shares of Aura Biosciences stock opened at $11.74 on Friday. The firm has a market capitalization of $581.63 million, a PE ratio of -6.31 and a beta of 0.37. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.38. The firm’s 50-day moving average price is $8.66 and its 200 day moving average price is $8.06.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. On average, sell-side analysts predict that Aura Biosciences will post -1.7 EPS for the current fiscal year.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the sale, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the sale, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.40% of the company’s stock.

Institutional Trading of Aura Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Aura Biosciences during the 3rd quarter worth approximately $169,000. Long Focus Capital Management LLC boosted its position in shares of Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after purchasing an additional 8,194 shares during the period. Renaissance Technologies LLC boosted its position in shares of Aura Biosciences by 26.3% during the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after purchasing an additional 15,000 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.